NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Niagen Bioscience Inc (NAGE) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. While the company shows strong revenue growth and potential upside in its injectable business, the recent decline in net income and EPS, coupled with a bearish technical setup and lack of significant trading signals, suggests waiting for a clearer entry point.
The MACD is positive and expanding, indicating bullish momentum, but the RSI is neutral at 52.93. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below the pivot level of 5.183 with key support at 4.78. This suggests a bearish short-term trend.
Strong full-year sales growth of 30% in 2025, potential upside in the injectable business, and plans to launch new products.
Decline in Q4 net income (-42.44% YoY) and EPS (-44.44% YoY), ongoing legal challenges regarding NMN's supplement status, and bearish technical indicators.
In Q4 2025, revenue increased by 16.19% YoY to $33.8 million, but net income dropped by 42.44% YoY to $4.13 million, and EPS fell by 44.44% YoY to 0.05. Gross margin improved slightly to 64.14%.
Canaccord analyst Susan Anderson maintains a Buy rating but lowered the price target from $14 to $13, citing strong demand in the core business and potential upside in the injectable business.
